CCND1 (Cyclin D1)

Critically, Ctnnb1 silencing in T cells abrogated the enhanced proliferation, TCM formation, and cytotoxic activity induced by SHP1-deficient DCs. DC-intrinsic SHP1 restrains central memory CD8+ T cell formation via the TCF-1/Wnt/β-catenin axis.

ER-negative and triple-negative effusions demonstrate more aggressive molecular features including enrichment of TP53 mutations and earlier effusion development. Effusion-based molecular testing yields clinically relevant genomic information in advanced breast cancer.

After lymphoma-directed therapy alone (R-CHOP/R-DHAP induction, autologous hematopoietic stem cell transplantation consolidation, and extended rituximab maintenance), both conditions achieved sustained remission...Both MCL and MN remained in remission for >2 years. This case highlights MCL-associated MN as a PLA2R/THSD7A/NELL-1 triple-negative entity where antineoplastic therapy alone induces renal remission, demonstrating both the paraneoplastic mechanism and the feasibility of intensive lymphoma treatment, including transplantation without renal compromise.

CCND1, POU5F1, SOX2, HNF1A, BRCA1, and FOXA1 were identified as key molecules that may serve as potential biomarkers for diagnosis and targeted therapy of NFPA.

Furthermore, EGCG-modulated miR-27a-3p affected key Wnt/β-catenin pathway markers, causing signal suppression, including suppression of a key Wnt-targeted gene and the G1 phase regulator cyclin-D1, which also indicated its potential against breast cancer. These results signify the therapeutic potential of EGCG and its potential implementation through the miR-27a/Wnt/β-catenin pathway axis, resulting in reduced breast cancer proliferation, metastasis, and relapse.

LMSCC16 also harbored two TP53 mutations and showed increased resistance to Cisplatin and Paclitaxel compared to established TSCC cell lines. In contrast, LMSCC16 showed significant modulation of OCT4, increased CCND1 and CCNB1 expression, and reduced CDH1 levels following treatment. We established two novel TSCC cell lines that represent clinically relevant models to explore TSCC carcinogenesis and therapeutic responses, particularly in non-smoking populations.

Within this research, the data showed the arrest of the cell cycle and the inhibition of the proliferation regulatory gene by Peruvoside were associated with suppression of lung cancer survival, proliferation, metastatic dissemination, and promotion of cell death.

Pdcd4 expression is downregulated in highly malignant DTIC-resistant melanoma cells and the resulting disruption in cell cycle control may contribute to drug resistance. Reactivating Pdcd4 to modulate cell cycle progression may offer a promising approach for overcoming chemotherapy resistance in patients with tumors.

Inhibition with ICG-001 significantly attenuated PY-induced fibrosis, confirming Wnt/β-catenin-dependent effects. These findings provide mechanistic insight into PY-induced renal injury and fibrosis.

Administering rhBMP-2 significantly suppressed tumor expansion in a mouse model of CRC, further supporting its potential as an antitumor agent. Collectively, these results indicate that rhBMP-2 mitigates CRC progression by activating the Hippo signaling pathway and suppressing YAP-mediated oncogenic processes, thereby highlighting its potential as a therapeutic agent that warrants further clinical evaluation.

Through systematic multi-cohort integration and machine-learning prioritization, CPVL was identified as a novel oncogenic driver in gastric cancer. CPVL promotes tumor growth via activation of the JAK2/STAT3 pathway and regulation of the Cyclin D1/CDK4/p27 axis, highlighting its potential as a diagnostic biomarker and therapeutic target.

Moreover, 12b-meta showed moderate human plasma stability, with 53.4% remaining after 240 min. These findings established the meta-tBu CA-DHA scaffold as a platform for a potential preclinical optimization in colorectal cancer drug discovery.